Epidarex Capital acquires Sirakoss by OssDsign

Daily Record Staff//November 3, 2020//

Listen to this article

Epidarex Capital, an Edinburg, United Kingdom-based life science venture firm with its U.S. base in Bethesda, acquired portfolio company Sirakoss by OssDsign, a Swedish medtech company, for $11 million plus milestone and royalty payments.

Sirakoss successfully developed Osteo3 ZP Putty, a nanosynthetic bone graft substitute to facilitate bone repair, which recently received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA). Osteo3 ZP Putty has been designed to provide surgeons with an innovative and easy-to-use product for filling voids during spine and trauma bone grafting procedures. The product complements OssDsign’s craniomaxillofacial portfolio and commercial activities in the US are expected to begin immediately.

Epidarex Capital led the 2014 Series A and subsequent financings of Sirakoss following its spin-out from the University of Aberdeen.

In October, the lead program of Epidarex Capital portfolio company Enterprise Therapeutics, a novel and potentially universal approach to treating cystic fibrosis, was acquired by Roche in a deal that included a £75 million upfront payment with additional milestone payments.

Enterprise will continue with its development of other novel therapies to improve the lives of patients suffering with respiratory disease. Epidarex was the founding investor in Enterprise in 2015 and was instrumental in shaping the business strategy with its scientific founders and management.